Abstract
We have read with interest the randomized trial comparing sirolimus-eluting stents (Cypher, Cordis) to thin-strut bare-metal stents (BMSs) (BeStent 2, Medtronic).1 Indeed, as the authors have previously pointed out, any novel treatment should be compared with the best performing control treatment, and thus, thin-strut BMS were the only correct benchmark for the thorough appraisal of drug-eluting stents (DESs). In addition, results of the study from Pache et al. 1 provide the first means to accurately test a novel and still controversial analytic tool, the adjusted indirect comparative meta-analysis.2 We have recently shown that, using their respective BMS control group as reference, different DESs can be indirectly compared by means of meta-analysis.3 Yet, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
